Bibliografia
1. Midha KK, et al. Bioequivalence: switchability and scaling. Eur J Pharm Sci 1998;6:87-91.
2. Nightingale SL, et al. Generic drugs and the prescribing physician. JAMA 1987;258:1200-1204.
3. Peterson GM. Generic Substitution of Antiepileptics: Need for a Balanced View. CNS Spectr (in press).
4. Berg MJ. What’s the problem with generic antiepileptic drugs? A call to action. Neurology 2007;68:1245-1246.
5. Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007;48:1825-1832.
6. Bialer M and Midha KK. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia 2007;51:941-950.
7. Perucca E, et al. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 2006;47(Suppl 5):16-20.
8. Andlin-Sobocki P, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl 1):1-27.
9. Haas JS, et al. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 2005;142:891-897.
10. Pugliatti M, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48:2224-2233.
11. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16:165-170.
12. Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578-1592.
13. Huskamp HA, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003;349(23):2224-2232.
14. Goldman DP, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004;291(19):2344-2350.
15. Ellis JJ, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Gen Intern Med 2004;19(6):638-645.
16. Roblin DW, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care 2005;43(10):951-959.
17. Pearce GA, et al. Bioequivalence: how, why, and what does it really mean? J Pharm Pract Res 2004;34(3):195-200.
18. Chen ML, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 2001;18:1645-1650.
19. Hauck WW, et al. Types of bioequivalence and related statistical considerations. Int J Clin Pharmacol Ther Toxicol 1992;30:181-187.
20. Crawford P, et al. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006;15:165-176.
21. Hauck WW and Anderson S. Individual bioequivalence: what matters to the patient. Stat Med 1991;10:959-960.
22. Hauck WW and Anderson S. Measuring switchability and prescribability: when is average bioequivalence sufficient? J Pharmacokinet Biopharm 1994;22:551-564.
23. Hauck WW, et al. A parametric approach to population bioequivalence. Stat Med 1997;16:441-454.
24. Midha KK, et al. Individual and average bioequivalence of highly variable drugs and drug products. J Pharm Sci 1997;86:1193-1197.
25. Anderson S and Hauck WW. Consideration of individual bioequivalence. J Pharmacokinet Biopharm 1990;18:259-273.
26. Chen ML. Individual bioequivalence—a regulatory update. J Biopharm Stat 1997;7:5-11.
27. Chen ML and Lesko LJ. Individual bioequivalence revisited. Clin Pharmacokinet 2001;40:701-706.
28. Walker E, Nowacki AS. Understanding equivalence and noninferiority testing. Gen Intern Med 2011;26(2):192-196.
29. Marasco RA and Ramsay RE. Epilepsy in the elderly: medications and pharmacokinetics. Consult Pharm 2009;24 Suppl A:10-16. 29. Schall R and Luus HG. On population and individual bioequivalence. Stat Med 1993;12:1109-1124.
30. Elkoshi Z, et al. Multiple-dose studies can be a more sensitive assessment for bioequivalence than single-dose studies: the case with omeprazole. Clin Drug Invest 2002;22:585-592.
31. Duh MS, et al.The risks and costs of multiple-generic substitution of topiramate. Neurology 2009;72:2122-2129.
32. Knoben JE, et al. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. Am J Hosp Pharm 1990;47(12):2696-2700.
33. Heaney DC and Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 2007;6:465-468.
34. Andermann F, et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007;48(3):464-469.
35. Guberman A and Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 2000;27:37-43.
36. Kramer G, et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav 2007;11:46-52.
|